76 related articles for article (PubMed ID: 21112630)
21. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
van der Spek E; Bloem AC; Lokhorst HM; van Kessel B; Bogers-Boer L; van de Donk NW
Leuk Res; 2009 Jan; 33(1):100-8. PubMed ID: 18621417
[TBL] [Abstract][Full Text] [Related]
22. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS
Br J Haematol; 2010 Aug; 150(3):313-25. PubMed ID: 20560971
[TBL] [Abstract][Full Text] [Related]
23. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma.
Khong T; Sharkey J; Spencer A
Haematologica; 2008 Jun; 93(6):860-9. PubMed ID: 18443271
[TBL] [Abstract][Full Text] [Related]
24. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
Lentzsch S; Rogers MS; LeBlanc R; Birsner AE; Shah JH; Treston AM; Anderson KC; D'Amato RJ
Cancer Res; 2002 Apr; 62(8):2300-5. PubMed ID: 11956087
[TBL] [Abstract][Full Text] [Related]
25. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
26. Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.
Zhang YW; Jiang XX; Chen QS; Shi WY; Wang L; Sun HD; Shen ZX; Chen Z; Chen SJ; Zhao WL
Exp Hematol; 2010 Mar; 38(3):191-201. PubMed ID: 20045442
[TBL] [Abstract][Full Text] [Related]
27. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
28. Drug insight: thalidomide as a treatment for multiple myeloma.
Kumar S; Anderson KC
Nat Clin Pract Oncol; 2005 May; 2(5):262-70. PubMed ID: 16264962
[TBL] [Abstract][Full Text] [Related]
29. Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: possible anti-myeloma mechanism of thalidomide.
Iguchi T; Yachide-Noguchi T; Hashimoto Y; Nakazato S; Sagawa M; Ikeda Y; Kizaki M
Int J Mol Med; 2008 Feb; 21(2):163-8. PubMed ID: 18204782
[TBL] [Abstract][Full Text] [Related]
30. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
32. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
Evans RP; Naber C; Steffler T; Checkland T; Maxwell CA; Keats JJ; Belch AR; Pilarski LM; Lai R; Reiman T
Br J Haematol; 2008 Feb; 140(3):295-302. PubMed ID: 18076711
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Hideshima T; Chauhan D; Hayashi T; Podar K; Akiyama M; Mitsiades C; MItsiades N; Gong B; Bonham L; de Vries P; Munshi N; Richardson PG; Singer JW; Anderson KC
Cancer Res; 2003 Dec; 63(23):8428-36. PubMed ID: 14679006
[TBL] [Abstract][Full Text] [Related]
34. Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells.
Renoir JM; Bouclier C; Seguin A; Marsaud V; Sola B
J Mol Endocrinol; 2008 Mar; 40(3):101-12. PubMed ID: 18316469
[TBL] [Abstract][Full Text] [Related]
35. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
36.
Schmeel LC; Schmeel FC; Schmidt-Wolf IGH
Anticancer Res; 2017 Jul; 37(7):3513-3520. PubMed ID: 28668840
[TBL] [Abstract][Full Text] [Related]
37. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report.
Sher T; Miller KC; Lee K; Chanan-Khan A
Clin Lymphoma Myeloma; 2009 Aug; 9(4):328-30. PubMed ID: 19717386
[TBL] [Abstract][Full Text] [Related]
38. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
[TBL] [Abstract][Full Text] [Related]
39. [Thalidomide with or without dexamethasone for refractory multiple myeloma].
Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ
Therapie; 2002; 57(6):524-9. PubMed ID: 12666259
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide in multiple myeloma.
Thomas SK; Richards TA; Weber DM
Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]